These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 9181307)
21. In-Vitro Activity of Silybin and Related Flavonolignans against Olías-Molero AI; Jiménez-Antón MD; Biedermann D; Corral MJ; Alunda JM Molecules; 2018 Jun; 23(7):. PubMed ID: 29954145 [TBL] [Abstract][Full Text] [Related]
22. Antiproliferative and ultrastructural effects of phenethylamine derivatives on promastigotes and amastigotes of Leishmania (Leishmania) infantum chagasi. Brasil PF; de Freitas JA; Barreto ALS; Adade CM; Reis de Sá LF; Constantino-Teles P; Toledo FT; de Sousa BA; Gonçalves AC; Romanos MTV; Comasseto JV; Dos Santos AA; Tessis AC; Souto-Padrón T; Soares RMA; Ferreira-Pereira A Parasitol Int; 2017 Apr; 66(2):47-55. PubMed ID: 27888011 [TBL] [Abstract][Full Text] [Related]
23. In vitro activity of amphotericin B cochleates against Leishmania chagasi. Sesana AM; Monti-Rocha R; Vinhas SA; Morais CG; Dietze R; Lemos EM Mem Inst Oswaldo Cruz; 2011 Mar; 106(2):251-3. PubMed ID: 21537689 [TBL] [Abstract][Full Text] [Related]
24. Antifungal susceptibility testing of Candida species by flow cytometry. Lee W; Kwak Y J Korean Med Sci; 1999 Feb; 14(1):21-6. PubMed ID: 10102519 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis. Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917 [TBL] [Abstract][Full Text] [Related]
26. Antileishmanial activity of a new 8-hydroxyquinoline derivative designed 7-[5'-(3'-phenylisoxazolino)methyl]-8-hydroxyquinoline: preliminary study. Dardari Z; Lemrani M; Bahloul A; Sebban A; Hassar M; Kitane S; Berrada M; Boudouma M Farmaco; 2004 Mar; 59(3):195-9. PubMed ID: 14987982 [TBL] [Abstract][Full Text] [Related]
27. Assessment of Leishmania cell lines expressing high levels of beta-galactosidase as alternative tools for the evaluation of anti-leishmanial drug activity. da Silva Santos AC; Moura DMN; Dos Santos TAR; de Melo Neto OP; Pereira VRA J Microbiol Methods; 2019 Nov; 166():105732. PubMed ID: 31629910 [TBL] [Abstract][Full Text] [Related]
28. In vitro antileishmanial effects of Physalis angulata root extract on Leishmania infantum. Da Silva BJM; Pereira SWG; Rodrigues APD; Do Nascimento JLM; Silva EO J Integr Med; 2018 Nov; 16(6):404-410. PubMed ID: 30195443 [TBL] [Abstract][Full Text] [Related]
29. Antileishmanial activity and evaluation of the mechanism of action of strychnobiflavone flavonoid isolated from Strychnos pseudoquina against Leishmania infantum. Lage PS; Chávez-Fumagalli MA; Mesquita JT; Mata LM; Fernandes SO; Cardoso VN; Soto M; Tavares CA; Leite JP; Tempone AG; Coelho EA Parasitol Res; 2015 Dec; 114(12):4625-35. PubMed ID: 26346453 [TBL] [Abstract][Full Text] [Related]
30. Flow cytometric detection of Leishmania parasites in human monocyte-derived macrophages: application to antileishmanial-drug testing. Di Giorgio C; Ridoux O; Delmas F; Azas N; Gasquet M; Timon-David P Antimicrob Agents Chemother; 2000 Nov; 44(11):3074-8. PubMed ID: 11036025 [TBL] [Abstract][Full Text] [Related]
31. In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum. Ordóñez-Gutiérrez L; Espada-Fernández R; Dea-Ayuela MA; Torrado JJ; Bolás-Fernandez F; Alunda JM Int J Antimicrob Agents; 2007 Oct; 30(4):325-9. PubMed ID: 17631982 [TBL] [Abstract][Full Text] [Related]
33. Old world Leishmania infantum cutaneous leishmaniasis unresponsive to liposomal amphotericin B treated with topical imiquimod. Hervás JA; Martín-Santiago A; Hervás D; Rojo E; Mena A; Rocamora V; Dueñas J Pediatr Infect Dis J; 2012 Jan; 31(1):97-100. PubMed ID: 21829140 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of second line drugs on antimonyl-resistant amastigotes of Leishmania infantum. Sereno D; Holzmuller P; Lemesre JL Acta Trop; 2000 Jan; 74(1):25-31. PubMed ID: 10643904 [TBL] [Abstract][Full Text] [Related]
35. Amphotericin B susceptibility testing of Candida lusitaniae isolates by flow cytofluorometry: comparison with the Etest and the NCCLS broth macrodilution method. Favel A; Peyron F; De Méo M; Michel-Nguyen A; Carrière J; Chastin C; Regli P J Antimicrob Chemother; 1999 Feb; 43(2):227-32. PubMed ID: 11252328 [TBL] [Abstract][Full Text] [Related]
36. Apoptosis-like cell death in Leishmania donovani treated with KalsomeTM10, a new liposomal amphotericin B. Shadab M; Jha B; Asad M; Deepthi M; Kamran M; Ali N PLoS One; 2017; 12(2):e0171306. PubMed ID: 28170432 [TBL] [Abstract][Full Text] [Related]
37. Combination therapy with nitazoxanide and amphotericin B, Glucantime®, miltefosine and sitamaquine against Leishmania (Leishmania) infantum intracellular amastigotes. Mesquita JT; Tempone AG; Reimão JQ Acta Trop; 2014 Feb; 130():112-6. PubMed ID: 24239532 [TBL] [Abstract][Full Text] [Related]
38. Novel dual-fluorescent flow cytometric approach for quantification of macrophages infected with Islek Z; Ucisik MH; Sahin F Parasitology; 2022 Jan; 149(1):44-50. PubMed ID: 34488918 [TBL] [Abstract][Full Text] [Related]
39. Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model. Paul M; Durand R; Fessi H; Rivollet D; Houin R; Astier A; Deniau M Antimicrob Agents Chemother; 1997 Aug; 41(8):1731-4. PubMed ID: 9257750 [TBL] [Abstract][Full Text] [Related]
40. Differential effects of polyamine derivative compounds against Leishmania infantum promastigotes and axenic amastigotes. Tavares J; Ouaissi A; Lin PK; Tomás A; Cordeiro-da-Silva A Int J Parasitol; 2005 May; 35(6):637-46. PubMed ID: 15862577 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]